Showing 1 - 4 results of 4 for search 'Tim Akhurst', query time: 0.03s Refine Results
  1. 1
    Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma?

    Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma? by Kenneth S. K. Yap, Ojas H. Mehta, Wing Fai Eddie Lau, Tim Akhurst, Satish Warrier, Alexander Heriot, Rodney J. Hicks

    Published 2018-11-01
    Get full text
    Article
  2. 2
    First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

    First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorect... by Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai

    Published 2019-12-01
    Get full text
    Article
  3. 3
    The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!

    The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball! by Te-Jui Hung, Luke McLean, Catherine Mitchell, Claire Pascoe, Nathan Lawrentschuk, Declan G. Murphy, Amir Iravani, Dalveer Singh, Michael S. Hofman, Lamiaa Zidan, Tim Akhurst, Jeremy Lewin, Rodney J. Hicks

    Published 2019-05-01
    Get full text
    Article
  4. 4
    ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

    ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSC... by Christian Wichmann, Sagun Parakh, Gerard G Hanna, Thomas John, Jason Callahan, Benjamin Blyth, Michael MacManus, Daniel Steinfort, Andrew M Scott, Lisa Devereux, Fiona Hegi-Johnson, Stacey E Rudd, Tim Akhurst, Peter Roselt, Jenny Trinh, Paul S Donnelly, Rod Hicks, Stephen Fox, Kate Burbury

    Published 2022-11-01
    Get full text
    Article

Search Tools: